<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-26245" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Optic Neuritis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Guier</surname>
            <given-names>Christian P.</given-names>
          </name>
          <aff>Mayo Clinic</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Stokkermans</surname>
            <given-names>Thomas J.</given-names>
          </name>
          <aff>University Hospitals of Cleveland</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Christian Guier declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Thomas Stokkermans declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>3</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-26245.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>This activity describes the evaluation and management of optic neuritis and details the role of the interprofessional team in managing patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the presentation of an adult patient with presenting with signs or symptoms consistently with optic neuritis.</p></list-item><list-item><p>Describe ophthalmic treatment considerations for patients presenting with recent onset optic neuritis.</p></list-item><list-item><p>Describe long-term systemic health considerations for patients presenting with optic neuritis.</p></list-item><list-item><p>Explain the importance of collaboration and communication amongst the interdisciplinary team to enhance care coordination and improve outcomes for patients affected by optic neuritis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26245&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26245">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-26245.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>A healthy optic nerve is a&#x000a0;crucial conduit for impulses generated within the layers of the retina to leave the eye. Electrical signals are initiated by the photoreceptors in response to incident light, modified by retinal bipolar cells, and transmitted through the optic nerves to the lateral geniculate bodies. Damage to the nerve fiber layer or optic nerve may compromise the quality of these signals.</p>
        <p>The term optic neuritis (ON) is used to describe a variety of conditions affecting the optimal function of the optic nerve. A wide range of conditions, including infections, trauma, vascular insufficiency, metastases, toxins, or nutritional deficiencies, may cause optic neuropathies, but this article focuses on optic neuritis (ON), an inflammatory condition that demyelinates the optic nerve and degrades vision in one or both eyes.</p>
      </sec>
      <sec id="article-26245.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The mechanism responsible for acute optic neuritis (ON) has not been definitively identified but it is&#x000a0;believed that an autoimmune reaction damages the myelin sheath that encompasses neurons within the optic nerve. Patients with documented autoimmune diseases <xref ref-type="bibr" rid="article-26245.r1">[1]</xref>&#x000a0;have a greater propensity for ON and there is a causal relationship between HLA DRB1,<xref ref-type="bibr" rid="article-26245.r2">[2]</xref> HLA-B27<xref ref-type="bibr" rid="article-26245.r3">[3]</xref> and ON. Some studies suggest that viral illnesses, which are known to precipitate auto-immune reactions, may induce ON attacks. ON may be one manifestation of a demyelinating disease that affects several areas of the central nervous system; ON is often the first clinical manifestation of demyelination.</p>
      </sec>
      <sec id="article-26245.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The annual incidence of new-onset ON has been reported between 0.56 and 5.1 cases per 100,000 <xref ref-type="bibr" rid="article-26245.r4">[4]</xref>. &#x000a0;</p>
        <p>Risk factors for ON include age (20 to 40 years), sex (female:male = 2:1), and race (Caucasian).</p>
        <p>Children infrequently develop bilateral ON but childhood disease is not believed to foreshadow the development of multiple sclerosis <xref ref-type="bibr" rid="article-26245.r5">[5]</xref>,<xref ref-type="bibr" rid="article-26245.r6">[6]</xref>.</p>
        <p>An increased incidence of multiple sclerosis (MS) in temperate climates has been proposed<xref ref-type="bibr" rid="article-26245.r3">[3]</xref>,<xref ref-type="bibr" rid="article-26245.r5">[5]</xref>.&#x000a0;</p>
        <p>Studies have identified that the northern United States and western Europe have more cases relative to equatorial regions&#x000a0;<xref ref-type="bibr" rid="article-26245.r6">[6]</xref>.</p>
      </sec>
      <sec id="article-26245.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Optic neuritis (ON) is one manifestation of central nervous system inflammation with resultant demyelination. Recurrent episodes of ON indicate a propensity toward developing more generalized diseases&#x000a0;<xref ref-type="bibr" rid="article-26245.r7">[7]</xref>&#x000a0;including MS, neuromyelitis optica spectrum disorders (NMOSC), and myelin oligodendrocyte glycoprotein-IgG (MOG)<xref ref-type="bibr" rid="article-26245.r8">[8]</xref>. The extent of axonal damage due to optic neuritis (ON) differs according to the causative condition.</p>
        <p>Optic neuritis is the initial inflammatory event in 15-20% of patients with MS <xref ref-type="bibr" rid="article-26245.r9">[9]</xref>,<xref ref-type="bibr" rid="article-26245.r10">[10]</xref>, and half of MS patients will eventually have had at least one ON attack within the prior 15 years (see <bold>Image.</bold> Optic Neuritis as an Indicator of Multiple Sclerosis). Multiple sclerosis (MS) occurs more commonly in temperate climates <xref ref-type="bibr" rid="article-26245.r11">[11]</xref>,<xref ref-type="bibr" rid="article-26245.r12">[12]</xref>&#x000a0;with more cases seen in the northern United States and western Europe as opposed to equatorial regions <xref ref-type="bibr" rid="article-26245.r13">[13]</xref>. Oligoclonal bands within the cerebral spinal fluid are pathognomonic for MS.</p>
        <p>Optic neuritis related vision loss in patients with NMOSD and MOG is usually more severe and results in larger scotomas. Since both disorders affect the optic nerve, chiasm, and optic tracts, bilateral vision loss is common. Damage often extends longitudinally into the spinal cord in both conditions.</p>
        <p>NMOSD is characterized by frequent ON attacks that cause severe bilateral vision loss with little chance of functional improvement. Spinal cord lesions that extend beyond three vertebral segments are typical of NMOSD and debilitating transverse myelitis often limits physical activities. Detection of AQP4-IgG antibodies confirms the diagnosis of NMOSD.</p>
        <p>MOG is also associated with significant bilateral visual impairment but marked ON-related papillitis occurs less frequently than with NMOSD. Marked enhancement of the optic nerve, nerve sheath, and periocular tissues is evident&#x000a0;with neural imaging studies. Compared to those with NMOSD, patients with MOG are more likely to experience improved visual function after ON and they may have lower spinal cord involvement. Males and females are affected with equal frequencies <xref ref-type="bibr" rid="article-26245.r14">[14]</xref>,<xref ref-type="bibr" rid="article-26245.r15">[15]</xref>.</p>
      </sec>
      <sec id="article-26245.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Optic neuritis usually presents with the acute onset of monocular eye pain and vision loss in a young adult. Pain is usually associated with eye movements and often precedes loss of vision. Patients often report having had similar events in the same or fellow eye.</p>
        <p>The degree of vision impairment may range from near-normal acuity to no light perception <xref ref-type="bibr" rid="article-26245.r16">[16]</xref>. Nearly any visual field defect may be seen on automated visual field testing but central scotomas are most common. Color perception is significantly impaired (red hues are notably desaturated) and contrast sensitivity is diminished. Patients may experience recurring photopsias. Vision loss may be exacerbated after exercise or elevation of body temperature (Uhthoff phenomenon).</p>
        <p>Optic disc swelling is seen on fundoscopy in one-third of patients during the active phase. In the absence of observable papillitis, signs and symptoms of ON are usually sufficient to establish the diagnosis of retrobulbar neuritis.</p>
        <p>Bilateral presentation, profound loss of vision, and absence of eye pain prior to vision loss, together with atypical neurologic findings should prompt the search for an alternative etiology. Visual symptoms due to ON tend to resolve over several weeks to months and visual function improves to near-normal levels after six months in the majority of cases. There are, however, instances in which qualitative visual changes persist for the duration of a patient&#x02019;s life <xref ref-type="bibr" rid="article-26245.r17">[17]</xref>,&#x000a0;<xref ref-type="bibr" rid="article-26245.r18">[18]</xref>.</p>
      </sec>
      <sec id="article-26245.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Clinical evaluation of suspected optic neuritis should include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Best-corrected visual acuity.</p>
          </list-item>
          <list-item>
            <p>Automated visual field testing.</p>
          </list-item>
          <list-item>
            <p>Color vision testing with particular attention to red desaturation.</p>
          </list-item>
          <list-item>
            <p>Pupillary examination with measurement of a relative afferent pupillary defect (RAPD).
<list list-type="bullet"><list-item><p>Note: A RAPD may not be present with bilateral, symmetric optic nerve involvement.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Optic nerve examination.</p>
          </list-item>
          <list-item>
            <p>Optical coherence tomography (OCT) evaluation of the retinal nerve fiber layer (RNFL).</p>
          </list-item>
        </list>
        <p>If clinical findings are consistent with ON, additional testing should include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Magnetic resonance imaging (MRI) of the brain and orbits with and without contrast to look for demyelinating disease.
<list list-type="bullet"><list-item><p>In the active phase, the affected optic nerve will enhance.</p></list-item><list-item><p>Demyelinating lesions within the brain confirm the diagnosis of multiple sclerosis (MS).
<list list-type="bullet"><list-item><p>Optic neuritis with two or more typical lesions (one of which is contrast enhancing) is sufficient to diagnose MS (McDonald criteria)</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Clinical findings suggestive of neuromyelitis optica spectrum disorder (NMOSD) should prompt serum NMO-IgG testing.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26245.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Visual function will return to near-normal levels over weeks to months whether or not treatment any treatment is initiated. However, visual recovery is hastened when treated with corticosteroid therapy.</p>
        <p>Based on the long-term results of the Optic Neuritis Treatment Trial (ONTT), the protocol for treating optic neuritis (ON) is widely accepted throughout the medical community.</p>
        <list list-type="bullet">
          <list-item>
            <p>Intravenous methylprednisolone (500-1000mg once daily) for three day</p>
          </list-item>
          <list-item>
            <p>followed by oral prednisone (1mg/kg once daily) for eleven days.
<list list-type="bullet"><list-item><p>Note that oral prednisone alone was found to increase the rate of recurrent ON attacks.</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>If lesions characteristic of multiple sclerosis (MS) are evident with magnetic resonance imaging (MRI), then immune-modulating therapies should be considered to delay subsequent attacks.</p>
      </sec>
      <sec id="article-26245.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis of optic neuritis includes the following conditions:</p>
        <list list-type="bullet">
          <list-item>
            <p>Inflammatory, demyelinating disease (classic)</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Idiopathic optic neuritis</p>
              </list-item>
              <list-item>
                <p>Multiple sclerosis</p>
              </list-item>
              <list-item>
                <p>Neuromyelitis optica</p>
              </list-item>
              <list-item>
                <p>Myelin oligodendrocyte glycoprotein (MOG) antibody disorder</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>Ischemic optic neuropathy</p>
          </list-item>
          <list-item>
            <p>Autoimmune disorders</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Systemic lupus erythematosus&#x000a0;</p>
              </list-item>
              <list-item>
                <p>Giant cell arteritis</p>
              </list-item>
              <list-item>
                <p>Sarcoidosis</p>
              </list-item>
              <list-item>
                <p>Behcet&#x02019;s disease</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>Infectious&#x000a0;<xref ref-type="bibr" rid="article-26245.r19">[19]</xref></p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Viral</p>
              </list-item>
              <list-item>
                <list list-type="bullet">
                  <list-item>
                    <p>Herpes simplex1 and 2</p>
                  </list-item>
                  <list-item>
                    <p>Varicella-Zoster</p>
                  </list-item>
                  <list-item>
                    <p>Cytomegalovirus</p>
                  </list-item>
                  <list-item>
                    <p>Less frequent:</p>
                  </list-item>
                  <list-item>
                    <list list-type="bullet">
                      <list-item>
                        <p>Human immunodeficiency, Epstein-Barr, Dengue fever, West Nile, Chikungunya</p>
                      </list-item>
                      <list-item>
                        <p>Measles, Mumps, Rubella, Influenza</p>
                      </list-item>
                    </list>
                  </list-item>
                </list>
              </list-item>
              <list-item>
                <p>Bacterial</p>
              </list-item>
              <list-item>
                <list list-type="bullet">
                  <list-item>
                    <p><italic toggle="yes">Bartonella henselae</italic> (Cat-scratch disease)</p>
                  </list-item>
                  <list-item>
                    <p><italic toggle="yes">Treponema pallidum</italic> (Syphilis)</p>
                  </list-item>
                  <list-item>
                    <p><italic toggle="yes">Borrelia burgdorferi</italic> (Lyme disease)</p>
                  </list-item>
                  <list-item>
                    <p><italic toggle="yes">Mycobacterium tuberculosis</italic> (Tuberculosis)</p>
                  </list-item>
                  <list-item>
                    <p>Less frequent:</p>
                  </list-item>
                  <list-item>
                    <list list-type="bullet">
                      <list-item>
                        <p>Rickettsioses, <italic toggle="yes">Coxiella burnetti</italic> (Q fever), <italic toggle="yes">Tropheryma whippleii</italic> (Whipple disease)</p>
                      </list-item>
                      <list-item>
                        <p>Leptospira, Brucella, <italic toggle="yes">Mycobacterium leprae</italic> (Leprosy)</p>
                      </list-item>
                    </list>
                  </list-item>
                </list>
              </list-item>
              <list-item>
                <p>Fungal</p>
              </list-item>
              <list-item>
                <list list-type="bullet">
                  <list-item>
                    <p><italic toggle="yes">Cryptococcus neoformans</italic> (Cryptococcus)</p>
                  </list-item>
                  <list-item>
                    <p>Candidiasis</p>
                  </list-item>
                  <list-item>
                    <p><italic toggle="yes">Histoplasma capsulatum</italic> (Histoplasmosis)</p>
                  </list-item>
                  <list-item>
                    <p><italic toggle="yes">Aspergillus fumigatus</italic> (Aspergillus)</p>
                  </list-item>
                  <list-item>
                    <p>Mucormycosis</p>
                  </list-item>
                </list>
              </list-item>
              <list-item>
                <p>Parasitic</p>
              </list-item>
              <list-item>
                <list list-type="bullet">
                  <list-item>
                    <p><italic toggle="yes">Toxoplasma gondii</italic> (Toxoplasmosis)</p>
                  </list-item>
                  <list-item>
                    <p><italic toggle="yes">Toxocara canis</italic> (Toxocariasis)</p>
                  </list-item>
                  <list-item>
                    <p>Diffuse unilateral subacute necrosis (DUSN)</p>
                  </list-item>
                </list>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>Drugs</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Ethambutol/isoniazid</p>
              </list-item>
              <list-item>
                <p>Chloramphenicol, sulfonamides</p>
              </list-item>
              <list-item>
                <p>Amiodarone, digitalis</p>
              </list-item>
              <list-item>
                <p>Quinine, chloroquine, hydroxychloroquine</p>
              </list-item>
              <list-item>
                <p>Methotrexate, vincristine, tamoxifens</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>Nutritional/toxic</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Vitamin B deficiencies, particularly vitamin B12</p>
              </list-item>
              <list-item>
                <p>Methanol/alcohol</p>
              </list-item>
              <list-item>
                <p>Tobacco</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>Compressive optic nerve lesions</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Most often associated with a slow, subtle onset of signs and symptoms</p>
              </list-item>
            </list>
          </list-item>
        </list>
      </sec>
      <sec id="article-26245.s10" sec-type="Pertinent Studies and Ongoing Trials">
        <title>Pertinent Studies and Ongoing Trials</title>
        <p>The standard treatment of acute ON was oral corticosteroids when the collaborative, multicenter Optic Neuritis Treatment Trial (ONTT)&#x000a0;<xref ref-type="bibr" rid="article-26245.r20">[20]</xref>sought to clarify the role of corticosteroid therapy. More than 450 patients were enrolled at 15 sites between 1988 and 1991. The average age of enrolled subjects was 32, and most were Caucasian (85%) and female (77%). Subjects were randomized to receive oral prednisone (1 mg/kg daily for two weeks) or intravenous methylprednisolone (250 mg every 6 hours for three days) followed by either oral prednisone for the balance of the two weeks or an oral placebo.&#x000a0;</p>
        <p>Most subjects in each cohort recovered visual function in the first 1 to 3 months. Visual improvement occurred more rapidly in subjects treated with intravenous methylprednisolone, but there was no difference in the cohorts receiving oral&#x000a0;corticosteroids and placebo. Visual acuity did not fully return&#x000a0;in many subjects with initial visual acuities of 20/200&#x000a0;or worse.&#x000a0;Visual outcomes at six months were similar in all cohorts but&#x000a0;optic neuritis recurred twice as often in subjects who received prednisone.&#x000a0;</p>
        <p>At one year there were no differences in visual function (acuity, visual field, color discrimination, and contrast sensitivity) between&#x000a0;subjects who received placebo and corticosteroids (VA of 20/40 or better: placebo (95%), intravenous methylprednisolone (94%), and oral prednisone (91%) <xref ref-type="bibr" rid="article-26245.r21">[21]</xref>.&#x000a0;Visual recovery <xref ref-type="bibr" rid="article-26245.r22">[22]</xref>,<xref ref-type="bibr" rid="article-26245.r23">[23]</xref>,<xref ref-type="bibr" rid="article-26245.r24">[24]</xref>,<xref ref-type="bibr" rid="article-26245.r25">[25]</xref>, visual field results <xref ref-type="bibr" rid="article-26245.r26">[26]</xref>,<xref ref-type="bibr" rid="article-26245.r27">[27]</xref>, and neurologic consequences of ON&#x000a0;<xref ref-type="bibr" rid="article-26245.r28">[28]</xref>,<xref ref-type="bibr" rid="article-26245.r29">[29]</xref>,<xref ref-type="bibr" rid="article-26245.r30">[30]</xref>,<xref ref-type="bibr" rid="article-26245.r31">[31]</xref>,<xref ref-type="bibr" rid="article-26245.r10">[10]</xref>,<xref ref-type="bibr" rid="article-26245.r32">[32]</xref>have been reported at three years 7864737<xref ref-type="bibr" rid="article-26245.r33">[33]</xref>,<xref ref-type="bibr" rid="article-26245.r34">[34]</xref>&#x000a0;and 15 years&#x000a0;<xref ref-type="bibr" rid="article-26245.r35">[35]</xref>,<xref ref-type="bibr" rid="article-26245.r36">[36]</xref>.</p>
        <p>Diagnostic and treatment guidelines of ON have evolved over time <xref ref-type="bibr" rid="article-26245.r37">[37]</xref>,<xref ref-type="bibr" rid="article-26245.r38">[38]</xref>,<xref ref-type="bibr" rid="article-26245.r39">[39]</xref>,<xref ref-type="bibr" rid="article-26245.r40">[40]</xref>to help physicians differentiate typical ON from the atypical variants associated with more complex neurologic disorders.</p>
      </sec>
      <sec id="article-26245.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis for patients with ON depends on the underlying etiology.</p>
        <p>Short-term: Pain with eye movement usually resolves within days to weeks. Visual acuity and color perception improve over two weeks to three months, and nearly 90% of patients achieve&#x000a0;near-normal function by six months. Only 3% of patients have BCVA of 20/200 or worse after 5 years&#x000a0;<xref ref-type="bibr" rid="article-26245.r22">[22]</xref>.</p>
        <p>Long-term: In 15-20% of cases optic neuritis precedes the development of multiple sclerosis <xref ref-type="bibr" rid="article-26245.r9">[9]</xref>,<xref ref-type="bibr" rid="article-26245.r10">[10]</xref>, and recurrent ON increases the risk of developing MS or neuromyelitis optica spectrum disorders (NMOSD) <xref ref-type="bibr" rid="article-26245.r7">[7]</xref>. Approximately 50% of patients with MS have had at least one ON attack within the prior 15 years.</p>
      </sec>
      <sec id="article-26245.s12" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>To reduce the potential for visual impairment, neurologic disabilities, and physical limitations, optic neuritis must be recognized&#x000a0;quickly and accurately.&#x000a0;</p>
        <p>Patients with acute optic neuritis and the following characteristics have a lower risk of developing multiple sclerosis:</p>
        <list list-type="bullet">
          <list-item>
            <p>No demyelinating lesions on MRI.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Optic disc swelling.</p>
          </list-item>
          <list-item>
            <p>Male gender.</p>
          </list-item>
        </list>
        <p>&#x000a0;Other causes of optic nerve disease should be considered when:</p>
        <list list-type="bullet">
          <list-item>
            <p>Vision loss is bilateral, especially in older patients.</p>
          </list-item>
          <list-item>
            <p>Deterioration in visual due to presumed optic neuritis persists without improvement after five weeks.</p>
          </list-item>
          <list-item>
            <p>Vision loss is not accompanied by eye pain.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Retinal hemorrhage or marked optic disc edema is present.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26245.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The management of the patient with optic neuritis (ON) requires the close coordination of a variety of healthcare professionals. &#x000a0;</p>
        <p>The initial treatment is managed by a neuro-ophthalmologist or a neurology team familiar with the guidelines derived by the Optic Neuritis Treatment Trial (ONTT).</p>
        <p>The probability&#x000a0;of developing multiple sclerosis (MS) within 15 years of the initial ON attack is 50%<xref ref-type="bibr" rid="article-26245.r10">[10]</xref>.</p>
        <p>For patients with MS or at high risk for developing MS,&#x000a0;an array of healthcare specialists come together to provide&#x000a0;comprehensive care.</p>
        <p>The healthcare team provides a wide range of services, some of which are listed below.</p>
        <p>A complete team will include a combination of the following providers:</p>
        <list list-type="bullet">
          <list-item>
            <p>Neurology team to manage the diagnosis and treatment.
<list list-type="bullet"><list-item><p>Neurologist</p></list-item><list-item><p>Advanced practice professionals (APP)
<list list-type="bullet"><list-item><p>Nurse practitioners and advanced practice nurses (NP)</p></list-item><list-item><p>Physician assistants (PA)</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Rehabilitation specialists to enhance strength, physical stability, and musculoskeletal function.
<list list-type="bullet"><list-item><p>Physical medicine and rehabilitation (PMR) physician management.</p></list-item><list-item><p>Physical therapists (PT) to facilitate strength, balance, range of motion, and alleviate musculoskeletal pain.</p></list-item><list-item><p>Occupational therapists (OT) to facilitate activities of daily living skills.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Medical specialists
<list list-type="bullet"><list-item><p>Mental health specialists
<list list-type="bullet"><list-item><p>Psychiatrists/psychologists to manage mental health concerns.</p></list-item><list-item><p>Clinical social workers to provide appropriate resources, advocate for patient rights.</p></list-item></list>
</p></list-item><list-item><p>Neuro-ophthalmologists to manage visual&#x000a0;deficiencies related to neurologic disease.</p></list-item><list-item><p>Low vision specialists present aids to ameliorate the barriers inherent to&#x000a0;diminished visual function.</p></list-item><list-item><p>Urologists/gynecologists</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Pharmacists to provide patient education and monitor the complex medication regimen.</p>
          </list-item>
          <list-item>
            <p>Primary care providers coordinate overall health status and manage concomitant conditions.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Well-being professionals provide lifestyle modifications that benefit nutrition, fitness, and resilience.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26245.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26245&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26245">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/eye-health/optic-neuritis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=26245">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/26245/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=26245">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-26245.s15">
        <fig id="article-26245.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Optic Neuritis as an Indicator of Multiple Sclerosis. Optic neuritis can be visualized through fundoscopy, which may indicate the presence of multiple sclerosis. Contributed by S Bhimji, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="opticneu" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-26245.s16">
        <title>References</title>
        <ref id="article-26245.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soelberg</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nilsson</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jarius</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Reindl</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wildemann</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lillevang</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Asgari</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Autoimmune and immunogenetic profile of patients with optic neuritis in a population-based cohort.</article-title>
            <source>Mult Scler Relat Disord</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>21</volume>
            <fpage>97</fpage>
            <page-range>97-102</page-range>
            <pub-id pub-id-type="pmid">29544193</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26245.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tuwir</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Dunne</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Crowley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Saddik</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cassidy</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>The relationship between HLA-DRB1 alleles and optic neuritis in Irish patients and the risk of developing multiple sclerosis.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2007</year>
            <month>Oct</month>
            <volume>91</volume>
            <issue>10</issue>
            <fpage>1288</fpage>
            <page-range>1288-92</page-range>
            <pub-id pub-id-type="pmid">17895416</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26245.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhao</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Optic neuritis with positive HLA-B27: Characteristic phenotype in the Chinese population.</article-title>
            <source>J Neurol Sci</source>
            <year>2016</year>
            <month>Mar</month>
            <day>15</day>
            <volume>362</volume>
            <fpage>100</fpage>
            <page-range>100-5</page-range>
            <pub-id pub-id-type="pmid">26944126</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26245.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mart&#x000ed;nez-Lapiscina</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Fraga-Pumar</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pastor</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>G&#x000f3;mez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Conesa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lozano-Rub&#x000ed;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez-Dalmau</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Alonso</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Villoslada</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Is the incidence of optic neuritis rising? Evidence from an epidemiological study in Barcelona (Spain), 2008-2012.</article-title>
            <source>J Neurol</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>261</volume>
            <issue>4</issue>
            <fpage>759</fpage>
            <page-range>759-67</page-range>
            <pub-id pub-id-type="pmid">24532201</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26245.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>P&#x000e9;rez-Cambrod&#x000ed;</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>G&#x000f3;mez-Hurtado Cubillana</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Merino-Su&#x000e1;rez</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Pi&#x000f1;ero-Llorens</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Laria-Ochaita</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Optic neuritis in pediatric population: a review in current tendencies of diagnosis and management.</article-title>
            <source>J Optom</source>
            <year>2014</year>
            <season>Jul-Sep</season>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>125</fpage>
            <page-range>125-30</page-range>
            <pub-id pub-id-type="pmid">25000867</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26245.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lucchinetti</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Kiers</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>O'Duffy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gomez</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Cross</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Leavitt</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for developing multiple sclerosis after childhood optic neuritis.</article-title>
            <source>Neurology</source>
            <year>1997</year>
            <month>Nov</month>
            <volume>49</volume>
            <issue>5</issue>
            <fpage>1413</fpage>
            <page-range>1413-8</page-range>
            <pub-id pub-id-type="pmid">9371931</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26245.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sellner</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Boggild</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Clanet</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hintzen</surname>
                <given-names>RQ</given-names>
              </name>
              <name>
                <surname>Illes</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Montalban</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Du Pasquier</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Polman</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Sorensen</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Hemmer</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>EFNS guidelines on diagnosis and management of neuromyelitis optica.</article-title>
            <source>Eur J Neurol</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>17</volume>
            <issue>8</issue>
            <fpage>1019</fpage>
            <page-range>1019-32</page-range>
            <pub-id pub-id-type="pmid">20528913</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26245.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>You</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Arunachalam</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fontes</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Parratt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Barnett</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Barton</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chitranshi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fraser</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Klistorner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yiannikas</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Differing Structural and Functional Patterns of Optic Nerve Damage in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder.</article-title>
            <source>Ophthalmology</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>126</volume>
            <issue>3</issue>
            <fpage>445</fpage>
            <page-range>445-453</page-range>
            <pub-id pub-id-type="pmid">30060979</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26245.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>S&#x000f8;rensen</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Frederiksen</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Br&#x000f8;nnum-Hansen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Petersen</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>Optic neuritis as onset manifestation of multiple sclerosis: a nationwide, long-term survey.</article-title>
            <source>Neurology</source>
            <year>1999</year>
            <month>Aug</month>
            <day>11</day>
            <volume>53</volume>
            <issue>3</issue>
            <fpage>473</fpage>
            <page-range>473-8</page-range>
            <pub-id pub-id-type="pmid">10449106</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26245.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <collab>Optic Neuritis Study Group</collab>
            <article-title>Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up.</article-title>
            <source>Arch Neurol</source>
            <year>2008</year>
            <month>Jun</month>
            <volume>65</volume>
            <issue>6</issue>
            <fpage>727</fpage>
            <page-range>727-32</page-range>
            <pub-id pub-id-type="pmid">18541792</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26245.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simpson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Blizzard</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Otahal</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Van der Mei</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>82</volume>
            <issue>10</issue>
            <fpage>1132</fpage>
            <page-range>1132-41</page-range>
            <pub-id pub-id-type="pmid">21478203</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26245.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tao</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>van der Mei</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Blizzard</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Havrdova</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Horakova</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Shaygannejad</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lugaresi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Izquierdo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Trojano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Duquette</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Girard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grand'Maison</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Grammond</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Alroughani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Terzi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Oreja-Guevara</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sajedi</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Iuliano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sola</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lechner-Scott</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pesch</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>Pucci</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bergamaschi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Barnett</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ramo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Singhal</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>LA Spitaleri</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Slee</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Verheul</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez Bola&#x000f1;os</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Amato</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Cristiano</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Granella</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hodgkinson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fiol</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>McCombe</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Saladino</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez Menoyo</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Shuey</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Vucic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Deri</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Arruda</surname>
                <given-names>WO</given-names>
              </name>
              <name>
                <surname>Butzkueven</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Spelman</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>BV</given-names>
              </name>
              <collab>MSBase Study Group</collab>
            </person-group>
            <article-title>Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>87</volume>
            <issue>12</issue>
            <fpage>1343</fpage>
            <page-range>1343-1349</page-range>
            <pub-id pub-id-type="pmid">27810919</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26245.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rodriguez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Siva</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cross</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Kurland</surname>
                <given-names>LT</given-names>
              </name>
            </person-group>
            <article-title>Optic neuritis: a population-based study in Olmsted County, Minnesota.</article-title>
            <source>Neurology</source>
            <year>1995</year>
            <month>Feb</month>
            <volume>45</volume>
            <issue>2</issue>
            <fpage>244</fpage>
            <page-range>244-50</page-range>
            <pub-id pub-id-type="pmid">7854520</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26245.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jurynczyk</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Messina</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Woodhall</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Raza</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Everett</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Roca-Fernandez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tackley</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hamid</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sheard</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reynolds</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chandratre</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hemingway</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jacob</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vincent</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Leite</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Waters</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Palace</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Clinical presentation and prognosis in MOG-antibody disease: a UK study.</article-title>
            <source>Brain</source>
            <year>2017</year>
            <month>Dec</month>
            <day>01</day>
            <volume>140</volume>
            <issue>12</issue>
            <fpage>3128</fpage>
            <page-range>3128-3138</page-range>
            <pub-id pub-id-type="pmid">29136091</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26245.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Seze</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>MOG-antibody neuromyelitis optica spectrum disorder: is it a separate disease?</article-title>
            <source>Brain</source>
            <year>2017</year>
            <month>Dec</month>
            <day>01</day>
            <volume>140</volume>
            <issue>12</issue>
            <fpage>3072</fpage>
            <page-range>3072-3075</page-range>
            <pub-id pub-id-type="pmid">29194504</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26245.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bermel</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Balcer</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>Optic neuritis and the evaluation of visual impairment in multiple sclerosis.</article-title>
            <source>Continuum (Minneap Minn)</source>
            <year>2013</year>
            <month>Aug</month>
            <volume>19</volume>
            <issue>4 Multiple Sclerosis</issue>
            <fpage>1074</fpage>
            <page-range>1074-86</page-range>
            <pub-id pub-id-type="pmid">23917102</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26245.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beck</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Cleary</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Backlund</surname>
                <given-names>JC</given-names>
              </name>
              <collab>Optic Neuritis Study Group</collab>
            </person-group>
            <article-title>The Course of Visual Recovery after Optic Neuritis: Experience of the Optic Neuritis Treatment Trial.</article-title>
            <source>Ophthalmology</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>127</volume>
            <issue>4S</issue>
            <fpage>S174</fpage>
            <page-range>S174-S181</page-range>
            <pub-id pub-id-type="pmid">32200819</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26245.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Longbrake</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Lancia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tutlam</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Trinkaus</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Naismith</surname>
                <given-names>RT</given-names>
              </name>
            </person-group>
            <article-title>Quantitative visual tests after poorly recovered optic neuritis due to multiple sclerosis.</article-title>
            <source>Mult Scler Relat Disord</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>10</volume>
            <fpage>198</fpage>
            <page-range>198-203</page-range>
            <pub-id pub-id-type="pmid">27919490</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26245.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kahloun</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Abroug</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ksiaa</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mahmoud</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zeghidi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zaouali</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Khairallah</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Infectious optic neuropathies: a clinical update.</article-title>
            <source>Eye Brain</source>
            <year>2015</year>
            <volume>7</volume>
            <fpage>59</fpage>
            <page-range>59-81</page-range>
            <pub-id pub-id-type="pmid">28539795</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26245.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beck</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Cleary</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Keltner</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Shults</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Kaufman</surname>
                <given-names>DI</given-names>
              </name>
              <name>
                <surname>Buckley</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Corbett</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Kupersmith</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>NR</given-names>
              </name>
            </person-group>
            <article-title>A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group.</article-title>
            <source>N Engl J Med</source>
            <year>1992</year>
            <month>Feb</month>
            <day>27</day>
            <volume>326</volume>
            <issue>9</issue>
            <fpage>581</fpage>
            <page-range>581-8</page-range>
            <pub-id pub-id-type="pmid">1734247</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26245.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beck</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Cleary</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Optic neuritis treatment trial. One-year follow-up results.</article-title>
            <source>Arch Ophthalmol</source>
            <year>1993</year>
            <month>Jun</month>
            <volume>111</volume>
            <issue>6</issue>
            <fpage>773</fpage>
            <page-range>773-5</page-range>
            <pub-id pub-id-type="pmid">8512477</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26245.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beck</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Cleary</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Backlund</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>The course of visual recovery after optic neuritis. Experience of the Optic Neuritis Treatment Trial.</article-title>
            <source>Ophthalmology</source>
            <year>1994</year>
            <month>Nov</month>
            <volume>101</volume>
            <issue>11</issue>
            <fpage>1771</fpage>
            <page-range>1771-8</page-range>
            <pub-id pub-id-type="pmid">7800355</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26245.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Long</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Beck</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Moke</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Blair</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Kip</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Gal</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>The SKILL Card test in optic neuritis: experience of the Optic Neuritis Treatment Trial. Smith-Kettlewell Institute Low Luminance. Optic Neuritis Study Group.</article-title>
            <source>J Neuroophthalmol</source>
            <year>2001</year>
            <month>Jun</month>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>124</fpage>
            <page-range>124-31</page-range>
            <pub-id pub-id-type="pmid">11450903</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26245.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beck</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Gal</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Bhatti</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Brodsky</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Buckley</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Chrousos</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Corbett</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Eggenberger</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Goodwin</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kaufman</surname>
                <given-names>DI</given-names>
              </name>
              <name>
                <surname>Keltner</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Kupersmith</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Moke</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Nazarian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Orengo-Nania</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Savino</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Shults</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Trobe</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Wall</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Xing</surname>
                <given-names>D</given-names>
              </name>
              <collab>Optic Neuritis Study Group</collab>
            </person-group>
            <article-title>Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2004</year>
            <month>Jan</month>
            <volume>137</volume>
            <issue>1</issue>
            <fpage>77</fpage>
            <page-range>77-83</page-range>
            <pub-id pub-id-type="pmid">14700647</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26245.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kupersmith</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Gal</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Beck</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Xing</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>N</given-names>
              </name>
              <collab>Optic Neuritis Study Group</collab>
            </person-group>
            <article-title>Visual function at baseline and 1 month in acute optic neuritis: predictors of visual outcome.</article-title>
            <source>Neurology</source>
            <year>2007</year>
            <month>Aug</month>
            <day>07</day>
            <volume>69</volume>
            <issue>6</issue>
            <fpage>508</fpage>
            <page-range>508-14</page-range>
            <pub-id pub-id-type="pmid">17679669</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26245.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Keltner</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Spurr</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Beck</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>Comparison of central and peripheral visual field properties in the optic neuritis treatment trial.</article-title>
            <source>Am J Ophthalmol</source>
            <year>1999</year>
            <month>Nov</month>
            <volume>128</volume>
            <issue>5</issue>
            <fpage>543</fpage>
            <page-range>543-53</page-range>
            <pub-id pub-id-type="pmid">10577521</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26245.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Keltner</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Cello</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Dontchev</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gal</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Beck</surname>
                <given-names>RW</given-names>
              </name>
              <collab>Optic Neuritis Study Group</collab>
            </person-group>
            <article-title>Visual field profile of optic neuritis: a final follow-up report from the optic neuritis treatment trial from baseline through 15 years.</article-title>
            <source>Arch Ophthalmol</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>128</volume>
            <issue>3</issue>
            <fpage>330</fpage>
            <page-range>330-7</page-range>
            <pub-id pub-id-type="pmid">20212204</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26245.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rolak</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Beck</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Paty</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Tourtellotte</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Whitaker</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Rudick</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Cerebrospinal fluid in acute optic neuritis: experience of the optic neuritis treatment trial.</article-title>
            <source>Neurology</source>
            <year>1996</year>
            <month>Feb</month>
            <volume>46</volume>
            <issue>2</issue>
            <fpage>368</fpage>
            <page-range>368-72</page-range>
            <pub-id pub-id-type="pmid">8614496</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26245.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beck</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>Clinically definite multiple sclerosis following optic neuritis.</article-title>
            <source>Ann Neurol</source>
            <year>1997</year>
            <month>Nov</month>
            <volume>42</volume>
            <issue>5</issue>
            <fpage>815</fpage>
            <page-range>815-6</page-range>
            <pub-id pub-id-type="pmid">9392585</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26245.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beck</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Trobe</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Moke</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Gal</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Xing</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bhatti</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Brodsky</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Buckley</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Chrousos</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Corbett</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Eggenberger</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Goodwin</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kaufman</surname>
                <given-names>DI</given-names>
              </name>
              <name>
                <surname>Keltner</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Kupersmith</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Nazarian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Orengo-Nania</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Savino</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Shults</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Wall</surname>
                <given-names>M</given-names>
              </name>
              <collab>Optic Neuritis Study Group</collab>
            </person-group>
            <article-title>High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial.</article-title>
            <source>Arch Ophthalmol</source>
            <year>2003</year>
            <month>Jul</month>
            <volume>121</volume>
            <issue>7</issue>
            <fpage>944</fpage>
            <page-range>944-9</page-range>
            <pub-id pub-id-type="pmid">12860795</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26245.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beck</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Gal</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Xing</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bhatti</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Brodsky</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Buckley</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Chrousos</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Corbett</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Eggenberger</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Goodwin</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kaufman</surname>
                <given-names>DI</given-names>
              </name>
              <name>
                <surname>Keltner</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Kupersmith</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Moke</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Nazarian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Orengo-Nania</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Savino</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Shults</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Trobe</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Wall</surname>
                <given-names>M</given-names>
              </name>
              <collab>Optic Neuritis Study Group</collab>
            </person-group>
            <article-title>Neurologic impairment 10 years after optic neuritis.</article-title>
            <source>Arch Neurol</source>
            <year>2004</year>
            <month>Sep</month>
            <volume>61</volume>
            <issue>9</issue>
            <fpage>1386</fpage>
            <page-range>1386-9</page-range>
            <pub-id pub-id-type="pmid">15364684</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26245.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beck</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Arrington</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Murtagh</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Cleary</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Kaufman</surname>
                <given-names>DI</given-names>
              </name>
            </person-group>
            <article-title>Brain magnetic resonance imaging in acute optic neuritis. Experience of the Optic Neuritis Study Group.</article-title>
            <source>Arch Neurol</source>
            <year>1993</year>
            <month>Aug</month>
            <volume>50</volume>
            <issue>8</issue>
            <fpage>841</fpage>
            <page-range>841-6</page-range>
            <pub-id pub-id-type="pmid">8352671</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26245.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beck</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>The optic neuritis treatment trial: three-year follow-up results.</article-title>
            <source>Arch Ophthalmol</source>
            <year>1995</year>
            <month>Feb</month>
            <volume>113</volume>
            <issue>2</issue>
            <fpage>136</fpage>
            <page-range>136-7</page-range>
            <pub-id pub-id-type="pmid">7864737</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26245.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cleary</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Beck</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Bourque</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Backlund</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Miskala</surname>
                <given-names>PH</given-names>
              </name>
            </person-group>
            <article-title>Visual symptoms after optic neuritis. Results from the Optic Neuritis Treatment Trial.</article-title>
            <source>J Neuroophthalmol</source>
            <year>1997</year>
            <month>Mar</month>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>18</fpage>
            <page-range>18-23; quiz 24-8</page-range>
            <pub-id pub-id-type="pmid">9093956</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26245.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <collab>Optic Neuritis Study Group</collab>
            <article-title>Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial.</article-title>
            <source>Ophthalmology</source>
            <year>2008</year>
            <month>Jun</month>
            <volume>115</volume>
            <issue>6</issue>
            <fpage>1079</fpage>
            <page-range>1079-1082.e5</page-range>
            <pub-id pub-id-type="pmid">17976727</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26245.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beck</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Gal</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Treatment of acute optic neuritis: a summary of findings from the optic neuritis treatment trial.</article-title>
            <source>Arch Ophthalmol</source>
            <year>2008</year>
            <month>Jul</month>
            <volume>126</volume>
            <issue>7</issue>
            <fpage>994</fpage>
            <page-range>994-5</page-range>
            <pub-id pub-id-type="pmid">18625951</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26245.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Katz</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Trobe</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Beck</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>The optic neuritis treatment trial: implications for clinicians.</article-title>
            <source>Semin Ophthalmol</source>
            <year>1995</year>
            <month>Sep</month>
            <volume>10</volume>
            <issue>3</issue>
            <fpage>214</fpage>
            <page-range>214-20</page-range>
            <pub-id pub-id-type="pmid">10159746</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26245.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beck</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Trobe</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>What we have learned from the Optic Neuritis Treatment Trial.</article-title>
            <source>Ophthalmology</source>
            <year>1995</year>
            <month>Oct</month>
            <volume>102</volume>
            <issue>10</issue>
            <fpage>1504</fpage>
            <page-range>1504-8</page-range>
            <pub-id pub-id-type="pmid">9097798</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26245.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gal</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Vedula</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Beck</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Corticosteroids for treating optic neuritis.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2012</year>
            <month>Apr</month>
            <day>18</day>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>CD001430</fpage>
            <pub-id pub-id-type="pmid">22513900</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26245.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vedula</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Brodney-Folse</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gal</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Beck</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Corticosteroids for treating optic neuritis.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2007</year>
            <month>Jan</month>
            <day>24</day>
            <issue>1</issue>
            <fpage>CD001430</fpage>
            <pub-id pub-id-type="pmid">17253459</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
